Sarepta Exercises its Exclusive Option to Acquire Myngonexus Therapeutics for $165M

 Sarepta Exercises its Exclusive Option to Acquire Myngonexus Therapeutics for $165M

Sarepta Exercises its Exclusive Option to Acquire Myngonexus Therapeutics for $165M

Shots:

  • Sarepta exercises its option to acquire Myonexus Therapeutics, in all stock transaction for $165M with its five Limb-girdle muscular dystrophy (LGMDs) gene therapies programs i.e LGMD2E, LGMD2D, LGMD2B, LGMD2L & LGMD2C
  • In May,2018 Sarepta and Myonexus collaborated to develop and advance multiple gene therapy programs for LGMD, paying $60M upfront & milestones, gaining excsluive option to acquire Myngonexus  
  • LGMD2E, LGMD2D, LGMD2B, LGMD2L & LGMD2C are gene therapy programs targeted for MYO-101 (P-I/II), MYO-102 (P-I/II), MYO-201 (P-I), MYO-301 & MYO-103 respectively

Click here to read full press release/ article | Ref: Sarepta Therapeutics | Image: Twitter

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post